101 – 110 of 121
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2017
-
Mark
Molecular classification of urothelial carcinoma : global mRNA classification versus tumour-cell phenotype classification
- Contribution to journal › Article
-
Mark
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
- Contribution to journal › Article
-
Mark
HER2 and EGFR amplification and expression in urothelial carcinoma occurs in distinct biological and molecular contexts
- Contribution to journal › Article
-
Mark
Frequent miRNA-convergent fusion gene events in breast cancer
- Contribution to journal › Article
-
Mark
Re : Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder
- Contribution to journal › Debate/Note/Editorial
- 2016
-
Mark
Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma
- Contribution to journal › Article
- 2015
-
Mark
On Molecular Classification of Bladder Cancer: Out of One, Many.
- Contribution to journal › Debate/Note/Editorial
-
Mark
A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.
- Contribution to journal › Article
-
Mark
Heterogeneous Challenges for Urologic Cancers.
- Contribution to journal › Debate/Note/Editorial
-
Mark
Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems.
- Contribution to journal › Article
